Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Vaxart Inc VXRT

Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Its development programs include pill vaccines designed to protect against norovirus (cause for acute gastroenteritis), coronavirus, including SARS-CoV-2 (COVID-19)), and influenza. In addition, it has generated preclinical data for its therapeutic vaccine candidate targeting cervical cancer and dysplasia caused by human papillomavirus. The Company's platform technology employs a vector-based approach and consists of various components, such as a vector (adenovirus type 5 (Ad5); an antigen (Ad5 DNA); an adjuvant (Toll-like receptor 3 (TLR3)), and its proprietary enteric-coated tablet.


NDAQ:VXRT - Post by User

<< Previous
Bullboard Posts
Next >>
Post by thevisionary2kon Feb 11, 2021 9:31am
306 Views
Post# 32536168

VXRT - StockInvest US

VXRT - StockInvest US

This morning StockInvest US released a VXRT stock and trend analysis, which included the following:

 

“Given the current short-term trend, the stock is expected to rise 22.78% during the next 3 months and, with a 90% probability hold a price between $9.41 and $29.18 at the end of this 3-month period.”

 

Further, the StockInvest US update states: “Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for Vaxart stock to perform well in the short-term.”

 

The end of the report states: “B. Riley is very positive to VXRT and gave it a "Buy" rating on December 03, 2020. The price target was set to $22.00.”

 

https://stockinvest.us/stock/VXRT

<< Previous
Bullboard Posts
Next >>